Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

Luyten and colleagues' prospective, randomized, multicenter, double-blind trial, therefore, compared continuous and intermittent celecoxib for the treatment of OA. All 123 patients had a flare of ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of recurrence, including liver (96%), lymph nodes (89%), abdominopelvic (86%) ...

Find all the commercial and brand names of generic drug called Celecoxib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Nearly a decade after reports first surfaced linking the prescription pain reliever celecoxib (Celebrex) to an increased risk of heart attack, and two years after the American Heart Association ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...